FORT WORTH, TX - (Accesswire - September 26, 2013) - Wound Management Technologies, Inc., (OTCQB: WNDM) and WellDyne, Inc., have signed a three year agreement for Marketing Consulting Services and Product Delivery for the CellerateRX(R) wound care and surgical product lines. Robert Lutz, Jr, Chairman and CEO, commented, "We are pleased to expand and formalize our relationship with WellDyne. They have been instrumental in the growing success of CellerateRX in surgical wounds in hospitals and also in assisting with awareness for our wound care products throughout the healthcare system. Together we are exploring other new marketing programs and market segments for CellerateRX." He further added, "The WellDyne product fulfillment centers will allow us to rapidly expand the distribution of our products throughout the world."
"We are excited about the extensive marketing opportunities we see with CellerateRX," stated Doug Taylor, Executive Vice President Sales and Market Development of WellDyne, Inc. "We have seen excellent results with the CellerateRX Surgical and Wound Care Products. The products’ efficacy and extremely competitive pricing combine to make a compelling solution for treating most wounds."
The agreement includes a warrant for WellDyne to purchase 4,500,000 shares or up to 4.9% of the common stock of Wound Management. See the related 8-k filing for further information.
CellerateRX(R) Activated Collagen is the Differentiator
CellerateRX(R)'s Activated Collagen(TM) (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to break down. In people with compromised health or circulation, the difference in wound healing can be significant. CellerateRX(R) is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. CellerateRX(R), which has widely been used for treatment of podiatric wounds, specifically diabetic ulcers, is now being utilized by other medical practices. These include but are not limited to the treatment of first and second degree burns, surgical wounds, and dermatological procedures. These additional procedures join the already extensive list of medical conditions CellerateRX(R) has successfully treated.
About Wound Management
Wound Management Technologies, Inc., is an emerging commercial stage company with its primary products in the $5 billion worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX(R), which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in the late stages of development. More information can be found on the company's web sites: http://www.wmgtech.com/ and http://www.celleraterx.com/.
About WellDyne, Inc.
WellDyne, Inc., has been in the health services business for over 17 years. WellDyne is the umbrella company that oversees its four divisions: WellDyneRx, US Specialty Care, NetCard Systems and WellCard. Through these four divisions, WellDyne provides a range of health services including Pharmacy Benefit Management, Mail Order Pharmacy, Specialty Drug Fulfillment and online access to a broad range of information on health, disease, pharmaceuticals and wellness.
Safe Harbor Statement
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
777 Main Street, Suite 3100
Fort Worth, TX 76102
Phone: (817) 820-7080
Source: Wound Management Technologies, Inc.